Abstract
Patients and clinicians often avoid initiating injectable therapy in type 2 diabetes (T2D)—fearing pain and complexity. The single-use pen (SUP) device contains a pre-filled syringe and automates needle insertion and retraction, and drug delivery. It was designed for subcutaneous delivery of 0.5 mL of dulaglutide, a once-weekly glucagon-like peptide-1 receptor agonist.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
